ArticleFrontiers in public health2026

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.

Yulong He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.